Innovative Gene Therapy Offers Hope for Severe Epileptic Encephalopathies

**Dravet syndrome** and similar *developmental epileptic encephalopathies (DEE)* pose serious challenges due to their onset in childhood, leading to **seizures, intellectual disabilities,** and sometimes **sudden death**. The condition is typically linked to genetic mutations, notably in the **SCN1A gene**. However, new research from Michigan Medicine shifts focus to the **SCN1B gene**, which is associated with even more severe forms of DEE. Researchers, guided by Chunling Chen, M.D., and Yukun Yuan, M.D., Ph.D., in Lori Isom’s lab, conducted studies using *mouse models* to evaluate a **gene therapy replacement** targeting this gene. Mice lacking the SCN1B gene suffer from severe outcomes, including seizures and 100% mortality within three weeks of birth. The gene therapy aimed to restore the expression of **beta-1 protein**, crucial for maintaining sodium channel regulation in the brain. Upon administering the therapy to newborn mice, researchers observed a noteworthy increase in survival rates, a reduction in seizure severity, and restoration of normal **neuron excitability**. This successful *proof-of-concept* research marks the beginning of developing a gene replacement therapy specifically for SCN1B-linked DEE. Although results may vary based on different forms of **SCN1B gene expression**, this pioneering effort provides new hope for tackling these rare and devastating conditions.